8-KMaterial AgreementsFinancial EventsExhibits & Filings

STRYKER CORP 8-K Report, Material Agreement (Feb 10, 2025)

Filed February 10, 2025For Securities:SYK

Summary

Stryker Corporation (SYK) announced the completion of a significant public offering of senior notes, raising a total of $3 billion. This offering consists of four tranches with varying maturities and interest rates: $500 million of 4.550% Notes due 2027, $700 million of 4.700% Notes due 2028, $800 million of 4.850% Notes due 2030, and $1 billion of 5.200% Notes due 2035. The proceeds from the issuance will be strategically allocated, with the 2030 and 2035 Notes intended to fund the tender offer for the acquisition of Inari Medical, Inc., and related expenses. The proceeds from the 2027 and 2028 Notes will be used for general corporate purposes, including working capital and potential acquisitions. The filing also outlines certain conditions related to the Inari Medical acquisition, specifically regarding the 2030 and 2035 Notes. Should the Inari acquisition not be consummated under specified terms by a certain date, these particular notes will be subject to a special mandatory redemption at 101% of their principal amount plus accrued interest. This structure highlights the company's commitment to its strategic growth initiatives while managing financial obligations and potential deal contingencies.

Key Highlights

  • 1Stryker Corporation successfully completed a $3 billion public offering of senior notes with maturities ranging from 2027 to 2035.
  • 2The offering includes $500M of 4.550% Notes due 2027, $700M of 4.700% Notes due 2027, $800M of 4.850% Notes due 2030, and $1B of 5.200% Notes due 2035.
  • 3Proceeds from the 2030 and 2035 Notes are earmarked to fund the acquisition of Inari Medical, Inc.
  • 4Proceeds from the 2027 and 2028 Notes will be used for general corporate purposes, including working capital and potential acquisitions.
  • 5The 2030 and 2035 Notes are subject to a special mandatory redemption provision if the Inari Medical acquisition is not consummated under specific conditions by a designated deadline.
  • 6The company expects to receive approximately $2.973 billion in net proceeds after deducting underwriting discounts and expenses.
  • 7The Indenture includes covenants that limit the Company's ability to incur certain liens, engage in sale and leaseback transactions, and undergo significant asset disposals.

Frequently Asked Questions

Stryker Corporation raised a total of $3 billion through the public offering of senior notes. The notes are divided into four tranches: $500 million of 4.550% Notes due 2027, $700 million of 4.700% Notes due 2028, $800 million of 4.850% Notes due 2030, and $1 billion of 5.200% Notes due 2035. Interest is payable semi-annually on February 10 and August 10.

The proceeds are allocated strategically. The net proceeds from the offering of the 2030 Notes and 2035 Notes ($1.8 billion total) are intended to finance the acquisition of Inari Medical, Inc., along with related fees and expenses. The net proceeds from the 2027 and 2028 Notes ($1.2 billion total) will be used for general corporate purposes, which may include working capital, other acquisitions, business opportunities, and debt repayment.

Yes, the 2030 Notes and 2035 Notes are subject to a special mandatory redemption. If Stryker does not consummate the tender offer for Inari Medical, Inc. by a specified date (the Special Mandatory Redemption End Date), or if the merger agreement is terminated before that date, the company will be required to redeem these specific notes in full at 101% of their principal amount, plus accrued interest. The 2027 and 2028 Notes are not subject to this specific mandatory redemption provision.

Stryker Corporation expects to receive approximately $2.973 billion in net proceeds from the offering, after accounting for the underwriting discount and estimated expenses.